Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals Inc. on June 24, 2025. The filing addresses a corporate governance event involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
The material change reported is the resignation of William Meury from the Board of Directors, effective June 24, 2025. Mr. Meury is departing to assume the role of President and Chief Executive Officer and a Board member at Incyte Corporation, a collaboration partner for Syndax's drug Niktimvo (axatilimab-csfr). The resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The only commentary provided confirms the amicable nature of the departure and the reason for the resignation.
Key Facts for Investor Verification
- William Meury resigned from the Syndax Board of Directors on June 24, 2025.
- The resignation is effective immediately and is not related to any disagreement with the Company.
- Mr. Meury is joining Incyte Corporation, a partner in the development of Niktimvo (axatilimab-csfr).
- Michael A. Metzger, Chief Executive Officer, signed the report on June 26, 2025.